Ask Warren

JONBUR Research · Initiation

Prestige BioPharma · 950210 · Biotech & Pharma

Prestige BioPharma: Tiny Revenue, Persistent Operating Losses and a Share Price Down 55.9% Over a Year

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Prestige BioPharma (KOSPI, Biotech & Pharma) has a market value of about ₩341.9B, while filed FY 2025 revenue was only about ₩10.2M and the operating loss was about ₩48.0M. The shares closed at ₩5,690 on 2026-10-16, down 55.9% over one year and up 7.6% over three months.

Written Oct 18, 2026 · Data as of Oct 16, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data shows a company still at an early commercial stage: revenue has appeared only recently and operating losses have continued every year since 2021. FY 2025 net income was positive at about ₩15.9M despite the operating loss, which suggests the profit came from items outside operations, though the data does not say which. The market value is very large relative to sales, so the price reflects expectations that the filings alone do not show. No valuation model estimate is available, and no recent news headlines are in the data. Foreign ownership is high at 63.5%, little changed from 63.7% sixty days ago. Retail investors were net buyers over 20 days while foreign and institutional investors were net sellers.

Business overview

Prestige BioPharma is a Biotech & Pharma company listed on KOSPI on 2021-02-05 and founded on 2015-07-13. It has 60,096,155 listed shares and a market capitalization of about ₩341.9B. Filed revenue was zero in 2021 and 2022, then ₩122K in 2023, ₩517K in 2024 and ₩10.2M in 2025. Recent filings include annual general meeting results, an auditor change application, independent director changes, an annual report for June 2026 (with an amendment), an amended major sales or supply contract notice, and changes in the largest shareholder's holdings.

Financial analysis

These figures come from filed financial statements. FY 2025 revenue was about ₩10.2M, up from about ₩517K in 2024, but from a very small base. The operating loss was about ₩48.0M, an operating margin of -470.1%. Operating losses were ₩47.1M in 2024, ₩52.6M in 2023, ₩48.7M in 2022 and ₩16.2M in 2021. Net income was ₩15.9M in 2025, after a loss of ₩24.7M in 2024, a profit of ₩13.3M in 2023 and a loss of ₩176.1M in 2022. ROE was 5.1% in 2025. Liabilities to equity were 46.7%. Cash was about ₩85.1M against borrowings of about ₩81.1M. Free cash flow was about -₩66.2M, so operations and investment consumed cash in the year.

Valuation

Current multiples are extreme because earnings and sales are tiny: P/E 21,507.1, P/B 1,128.5 and P/S 33,474.7, with no EV/EBITDA available and a 0.0% dividend yield. Year-end P/B ranged from 1,324.7 to 2,872.9 across 2021-2025, so the current P/B is lower than its own history, though still very high. Peers show far lower multiples: Samsung Biologics P/E 30.3 and P/B 7.2, Celltrion 28.6 and 2.5, Alteogen 84.4 and 30.4, Yuhan 25.0 and 2.5, and SK biopharmaceuticals 14.3 and 5.6. The valuation model could not produce an estimate for this company, so there is no model estimate per share to compare with the ₩5,690 price.

Catalysts

  • The amended major sales or supply contract notice filed on 2026-08-25 may bear on future revenue, though the data does not give the terms.
  • The annual report for June 2026 and its amendment, filed 2026-09-22 and 2026-09-23, give fresh figures that investors can review.
  • The 2026-09-29 filings on an external auditor change and independent director appointments may affect governance and reporting.
  • Changes in the largest shareholder's holdings and the 5%+ holding report, both filed 2026-09-01, show ownership shifts worth watching.
  • Retail net buying of ₩243.9M over 20 days against foreign and institutional selling shows a split among investor groups.

Risks

  • Operating losses have continued in every year from 2021 to 2025, with an operating margin of -470.1% in FY 2025.
  • Free cash flow of -₩66.2M and borrowings of ₩81.1M, close to cash of ₩85.1M, could pressure funding.
  • The valuation multiples are extremely high compared with peers and rest on very small earnings and sales.
  • The FY 2025 net profit came despite an operating loss, so it may not repeat.
  • The share price is 60.0% below its 52-week high of ₩14,120 and fell 55.9% over one year, showing high volatility.

Closing view

The filings show a company whose revenue is only beginning to appear while operating losses remain large and cash is being used. The market value is very large relative to current sales and profit, and no model estimate is available to anchor it. Foreign ownership is stable and recent filings point to contract, governance and ownership changes, but the data gives no news and no short-interest figure. Investors should weigh the early stage of the numbers against the high price multiples and make their own assessment.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 18, 2026InitiationStart of coverage (reader request)Prestige BioPharma: Tiny Revenue, Persistent Operating Losses and a Share Price Down 55.9% Over a Year

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information